TickerFacts.

Sana Biotechnology, Inc. (SANA): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2023-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$131.98M
Year ended 2025-12-31
$124.48M
Trailing 12 months to 2026-06-30
$285.88M2019-12-31: $99.59M2020-12-31: $132.94M2021-12-31: $248.63M2022-12-31: $285.88M2023-12-31: $261.81M2024-12-31: $215.67M2025-12-31: $131.98M$131.98M
2019-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$131.98M-38.8%2026-03-03, From 2025-01-01
2024-12-31$215.67M-17.6%2026-03-03, From 2024-01-01
2023-12-31$261.81Mn/c2026-03-03, From 2023-01-01
2022-12-31$285.88M+15.0%2025-03-17, From 2022-01-01
2021-12-31$248.63M+87.0%2024-02-29, From 2021-01-01
2020-12-31$132.94M+33.5%2023-03-16, From 2020-01-01
2019-12-31$99.59Mn/a2022-03-16, From 2019-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Sana Biotechnology, Inc. (SANA)2025-12-31$131.98M-38.8%
Allogene Therapeutics, Inc. (ALLO)2025-12-31$150.15M-21.9%
Scholar Rock Holding Corp (SRRK)2025-12-31$208.44M+12.9%
Maze Therapeutics, Inc. (MAZE)2025-12-31$108.45M+29.9%
Cullinan Therapeutics, Inc. (CGEM)2025-12-31$187.40M+31.1%
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31$141.50M+16.4%
REGENXBIO Inc. (RGNX)2025-12-31$228.30M+9.5%
Vor Biopharma Inc. (VOR)2025-12-31$321.53M+244.6%
Scilex Holding Co (SCLX)2025-12-31$20.71M+114.8%

Compare SANA, ALLO, SRRK, MAZE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗